Combination of HER2-Targeted Antibodies (Trastuzumab plus Pertuzumab) is Effective Against HER2 Amplified Ovarian Cancer Xenograft Models

被引：0
|
作者：
Langdon, S. P. [1 ]
Sims, A. H. [1 ]
Harrison, D. J. [2 ]
机构：
[1] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[2] Univ St Andrews, St Andrews, Fife, Scotland
来源：
JOURNAL OF PATHOLOGY | 2013年 / 231卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [21] ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB plus DOCETAXEL FOR TREATMENT OF PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER AGAINST TREATMENT WITH TRASTUZUMAB plus DOCETAXEL plus PLACEBO, IN THE VENEZUELAN CONTEXT
    Romero, M.
    Huerfano, L. M.
    Acero, G.
    VALUE IN HEALTH, 2015, 18 (07) : A822 - A822
  • [22] Comparison of paclitaxel plus T-DM1 and pertuzumab versus paclitaxel plus trastuzumab and pertuzumab with carboplatin for HER2 overexpressed breast cancer models
    Sun, Yuliang
    Lin, Xiaoqian
    Jepperson, Tyler
    Williams, Casey
    De, Pradip
    Leyland-Jones, Brian
    CANCER RESEARCH, 2018, 78 (04)
  • [23] Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
    Yamashita-Kashima, Yoriko
    Iijima, Shigeyuki
    Yorozu, Keigo
    Furugaki, Koh
    Kurasawa, Mitsue
    Ohta, Masateru
    Fujimoto-Ouchi, Kaori
    CLINICAL CANCER RESEARCH, 2011, 17 (15) : 5060 - 5070
  • [24] EFFICACY OF HER2-TARGETED THERAPY FOR HER2 POSITIVE BREAST CANCER ACCORDING TO HR STATUS
    Murata, T.
    Takahashi, M.
    Hayashida, T.
    Hirose, S.
    Jinno, H.
    Kitagawa, Y.
    BREAST, 2013, 22 : S104 - S104
  • [25] The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies
    Freudenberg, Jaclyn A.
    Wang, Qiang
    Katsumata, Makoto
    Drebin, Jeffrey
    Nagatomo, Izumi
    Greene, Mark I.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2009, 87 (01) : 1 - 11
  • [26] Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
    Canonici, Alexandra
    Gijsen, Merel
    Mullooly, Maeve
    Bennett, Ruth
    Bouguern, Noujoude
    Pedersen, Kasper
    O'Brien, Neil A.
    Roxanis, Ioannis
    Li, Ji-Liang
    Bridge, Esther
    Finn, Richard
    Slamon, Dennis
    McGowan, Patricia
    Duffy, Michael J.
    O'Donovan, Norma
    Crown, John
    Kong, Anthony
    ONCOTARGET, 2013, 4 (10) : 1592 - 1605
  • [27] Activating HER2 mutations promote oncogenesis and resistance to HER2-targeted therapies in breast cancer
    Zuo, Wen-Jia
    Jiang, Yi-Zhou
    Yu, Ke-Da
    Shao, Zhi-Ming
    CANCER RESEARCH, 2015, 75
  • [28] Hormone receptor status might be a determinant for HER2 loss after HER2-targeted treatment in HER2 positive breast cancer patients
    Altundag, Kadri
    JOURNAL OF BUON, 2019, 24 (05): : 2206 - 2206
  • [29] A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2-advanced breast cancer patients with HER2 mutations
    Ma, Jing
    Li, Xuelu
    Zhang, Qianran
    Li, Ning
    Sun, Siwen
    Zhao, Shanshan
    Zhao, Zuowei
    Li, Man
    TRANSLATIONAL ONCOLOGY, 2022, 21
  • [30] Handling of anti-HER2 antibodies, trastuzumab and pertuzumab, in patients with HER2-positive breast cancer
    Araki, Kazuhiro
    Ito, Yoshinori
    ANNALS OF ONCOLOGY, 2015, 26 : 48 - 48
12345